{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:02:58Z","timestamp":1777896178501,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bbrc.2026.153747","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:19:58Z","timestamp":1775603998000},"page":"153747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oncolytic human adenovirus 5 (H101) modulates cell cycle progression in HPV16-positive tumors"],"prefix":"10.1016","volume":"818","author":[{"given":"Dong","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153747_bib1","article-title":"Role of TRIM37 in cervical cancer: its effects on tumor cells proliferation","author":"Sun","year":"2025","journal-title":"Migr. Invasion"},{"key":"10.1016\/j.bbrc.2026.153747_bib2","doi-asserted-by":"crossref","DOI":"10.31083\/BJHM50727","article-title":"Prevention and diagnosis of cervical cancers in the UK and Europe: what have we learned in the last 10 years and what is next?","volume":"87","author":"Williams","year":"2026","journal-title":"Br. J. Hosp. Med."},{"key":"10.1016\/j.bbrc.2026.153747_bib3","article-title":"The research progress on radiation resistance of cervical cancer","volume":"14","author":"Liang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.153747_bib4","article-title":"Correlation between human papillomavirus viral load and cervical lesions classification: a review of current research","volume":"10","author":"Zhou","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.bbrc.2026.153747_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051418","article-title":"The impact of human papilloma viruses, matrix metallo-proteinases and HIV protease inhibitors on the onset and progression of uterine cervix epithelial tumors: a review of preclinical and clinical studies","volume":"19","author":"Barillari","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153747_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.30623","article-title":"Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review","volume":"141","author":"Hoffman","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.153747_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.826771","article-title":"Co-Delivery of p53 restored and E7 targeted nucleic acids by poly (Beta-Amino ester) complex nanoparticles for the treatment of HPV related cervical lesions","volume":"13","author":"Xiong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153747_bib8","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1038\/s41467-019-12794-2","article-title":"Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy","volume":"10","author":"Huang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.153747_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients","volume":"30","author":"Garc\u00eda","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbrc.2026.153747_bib10","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.153747_bib11","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1002\/jcp.27850","article-title":"Oncolytic adenovirus: a tool for cancer therapy in combination with other therapeutic approaches","volume":"234","author":"Goradel","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbrc.2026.153747_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14715\/cmb\/2017.63.7.1","article-title":"Oncolytic E1B 55KDa-deleted adenovirus replication is independent of p53 levels in cancer cells","volume":"63","author":"Abbas","year":"2017","journal-title":"Cell. Mol. Biol. (Noisy-Le-Grand)"},{"key":"10.1016\/j.bbrc.2026.153747_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7150\/jca.16406","article-title":"11R-P53 and GM-CSF expressing oncolytic adenovirus target cancer stem cells with enhanced synergistic activity","volume":"8","author":"Lv","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbrc.2026.153747_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbrc.2026.153747_bib15","doi-asserted-by":"crossref","first-page":"18041","DOI":"10.18632\/oncotarget.24710","article-title":"Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer","volume":"9","author":"Salzwedel","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.153747_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.752504","article-title":"A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: a retrospective cohort study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.153747_bib17","article-title":"Efficacy and safety of recombinant human adenovirus type 5 (H101) in persistent, recurrent, or metastatic gynecologic malignancies: a retrospective study","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.153747_bib18","first-page":"80","article-title":"Application of comprehensive nursing intervention in treatment of intratumoral injection of recombinant human adenovirus type 5 combined with chemotherapy for patients with recurrent cervical cancer","volume":"13","author":"wen","year":"2016","journal-title":"Nurs. Pract. Res."},{"key":"10.1016\/j.bbrc.2026.153747_bib19","first-page":"49","article-title":"Nursing of nine recurrent cervical cancer patients receiving intratumor injection of type 5 adenovirus recombinant with chemotherapy","volume":"22","author":"Hongjuan","year":"2015","journal-title":"J. Nurs."},{"key":"10.1016\/j.bbrc.2026.153747_bib20","first-page":"453","article-title":"Clinical value of recombinant human adenovirus type 5 in transarterial chemoembolization in patients with cervical cancer","volume":"31","author":"ping","year":"2015","journal-title":"Chin. J. Pract. Gynecol. Obstetrics"},{"key":"10.1016\/j.bbrc.2026.153747_bib21","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1111\/1759-7714.15101","article-title":"Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: a multicenter, observational, real-world study","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.bbrc.2026.153747_bib22","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.3389\/fmicb.2019.02483","article-title":"Ubiquitination of the HPV Oncoprotein E6 is critical for E6\/E6AP-Mediated p53 degradation","volume":"10","author":"Li","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bbrc.2026.153747_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1006\/gyno.1994.1304","article-title":"p53 expression and genetic evidence for viral infection in intraepithelial neoplasia of the uterine cervix","volume":"55","author":"Vecchione","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbrc.2026.153747_bib24","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1002\/jcb.27863","article-title":"The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability","volume":"120","author":"Li","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2026.153747_bib25","article-title":"HPV16 E6 promoting cervical cancer progression through down-regulation of miR-320a to increase TOP2A expression","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2026.153747_bib26","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1038\/s41598-017-02831-9","article-title":"Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway","volume":"7","author":"Fischer","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.153747_bib27","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","article-title":"Requirement for p53 and p21 to sustain G2 arrest after DNA damage","volume":"282","author":"Bunz","year":"1998","journal-title":"Science"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26005115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26005115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:10:52Z","timestamp":1777623052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26005115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"alternative-id":["S0006291X26005115"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153747","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic human adenovirus 5 (H101) modulates cell cycle progression in HPV16-positive tumors","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153747"}}